Quick Facts

• Primary Use: Management of elevated fluid pressure within the eye.
• Conditions Addressed: Open-angle glaucoma and ocular hypertension.
• Goal of Therapy: Supports the long-term control of eye pressure.

---

Zitodor is a prescription medication utilized in ophthalmology for the management of certain eye conditions. The primary therapeutic domain for this medication is the reduction of elevated intraocular pressure (IOP). This elevated pressure is a key factor in conditions that can affect vision over time.

Zitodor is indicated for use in adult patients diagnosed with open-angle glaucoma or ocular hypertension. It is a component of a comprehensive treatment strategy intended to help control the pressure within the eye. Effective management of intraocular pressure is considered a standard of care for these conditions.

It may be used alone or in conjunction with other topical ophthalmic agents to achieve the desired level of pressure reduction. This medication supports the overall treatment plan and is part of the established medical therapy for controlling the fluid pressure inside the eye.

Who can and cannot use Zitodor?

The eligibility for using Zitodor (Dorzolamide/Timolol) is strictly determined by official regulatory documents, primarily based on the patient's existing health conditions and age, due to the potential for systemic absorption of the active components.

Contraindications and Restrictions

Contraindications (Must Not Use):

• Patients with bronchial asthma, a history of it, or severe Chronic Obstructive Pulmonary Disease (COPD).
• Individuals with specific cardiac conditions, including sinus bradycardia, second or third-degree atrioventricular (AV) block (uncontrolled by a pacemaker), overt cardiac failure, or cardiogenic shock.
• Known hypersensitivity to the active ingredients or any component, including a sulphonamide allergy.

Use is Not Recommended:

• Patients with severe renal impairment or hyperchloraemic acidosis.
• Patients who are pregnant or breastfeeding.
• Patients concurrently using an oral carbonic anhydrase inhibitor.

Age-Group Eligibility:

Zitodor is indicated for use in adult patients (aged 18 years). Safety and efficacy have not been established in children younger than 2 years of age. Use in older adults requires no specific dose adjustment, though caution is advised.

Use with Caution:

• Patients with hepatic impairment (as studies are limited).
• Patients with labile diabetes or those prone to spontaneous hypoglycaemia.

The official interaction profile for Zitodor (Dorzolamide/Timolol) is defined by the potential for additive systemic effects arising from the absorption of both active components. Regulatory documents stipulate several restrictions on co-administration to manage this risk.

Concomitant use with other oral carbonic anhydrase inhibitors is not recommended due to the potential for increased systemic effects of carbonic anhydrase inhibition. Similarly, co-administration with other topical beta-adrenergic blocking agents is also not recommended to avoid additive systemic beta-blockade. Caution is advised when the product is combined with systemic beta-adrenergic blocking agents, calcium antagonists, or digitalis, as these combinations may reinforce effects such as hypotension or the prolongation of atrioventricular conduction time. Close observation is required when combined with catecholamine-depleting drugs like reserpine. Furthermore, inhibitors of the CYP2D6 enzyme, such as quinidine or SSRIs, may potentiate the systemic beta-blockade effects.

Regarding administration procedures, if more than one topical ophthalmic medication is used, regulatory information mandates a minimum separation of five minutes between applications. Caution must also be exercised in patients with severe renal impairment (CrCl <30 mL/min), as the predominant renal excretion of dorzolamide raises the potential for increased systemic exposure. The combination with high-dose salicylate therapy requires consideration for potential acid-base disturbances.

The mechanism of action for this combination relies on simultaneously targeting two distinct pathways that regulate the production of fluid within the eye, resulting in a reduction of the intraocular pressure.

Inhibition of Fluid Precursor Synthesis (Dorzolamide)

This domain covers the action of Dorzolamide, which functions as an inhibitor of the enzyme Carbonic Anhydrase II (CA-II) in the ciliary body. By inhibiting this enzyme, the formation of bicarbonate ions ( HCO3^-) is reduced, thereby attenuating the osmotic gradient that facilitates active transport of water and ions into the eye.

Modulation of Secretory Signaling (Timolol)

This domain focuses on the complementary action of Timolol, a non-selective beta-adrenergic receptor antagonist. Timolol blocks beta1 and beta2 receptors on the ciliary epithelium, dampening the sympathetic signaling cascade (involving cyclic AMP) that typically stimulates and promotes fluid secretion. This antagonism causes a resulting decrease in the rate of fluid formation.

The combined, dual-action mechanism reduces the fundamental process of aqueous humor secretion (inflow) at two distinct molecular steps, resulting in a physiological decrease in pressure within the eye.

Administration Method

Zitodor is typically administered as an ophthalmic solution. The process involves placing the prescribed number of drops into the affected eye or eyes. To ensure the solution is distributed evenly and to prevent contamination, the dropper tip should not come into contact with the eye, eyelids, or any other surfaces.

Application Steps

When applying the eye drops, the head is tilted back slightly while the lower eyelid is gently pulled down to create a small pocket. The bottle is held upside down near the eye, and pressure is applied to release the drop. After the drop is instilled, the eye is closed for a short period. Applying light pressure to the inner corner of the eye, near the nose, can help keep the liquid from draining into the tear duct.

Usage with Contact Lenses

If contact lenses are worn, they should be removed prior to the administration of the eye drops. This is because certain components of the solution may be absorbed by soft contact lenses. Lenses can generally be reinserted after a short waiting period following the application.

Multiple Ophthalmic Medications

In cases where more than one type of eye drop is being used, a specific interval of time is maintained between the application of each different medication. This ensures that the first solution is not washed out by the second and allows for proper absorption of each treatment.

Research evidence / Overview of Studies for Zitodor

Evidence for use in Open-Angle Glaucoma and Ocular Hypertension

The primary research for this combination medicine was evaluated in adult patients with Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH). Studies mainly used Randomized Controlled Trials (RCTs), which are considered the established structure for clinical evaluation. These trials focused on measuring the change in Intraocular Pressure (IOP). Researchers measured IOP from the starting level and monitored how it evolved over defined time intervals.

The findings from these large-scale studies describe the patterns observed in the measurement of IOP. Specifically, the data show patterns related to the measurement of pressure change in the eye within the observed populations. The evidence contributes to the broader evidence landscape regarding IOP measurement patterns.

What remains uncertain is the long-term clinical outcome. While the immediate and medium-term IOP measurements are well-studied, there is limited information for long-term outcomes that directly examine how Zitodor impacts the progression of glaucoma-related damage over periods of many years.

---

Studies Comparing Combination vs. Individual Components

A significant portion of the research examined the measurement patterns of the fixed-dose combination of dorzolamide and timolol versus using each of its components as a single-agent treatment (monotherapy). The comparative studies were designed to measure the patterns of pressure measurement when using the combination versus using the individual components. The comparative studies described patterns where the IOP measurements for the combination were reported to differ from the patterns observed with monotherapy. Research also reported that the measurements for the combination were generally comparable to those when the two components were administered separately (concomitantly).

---

Research on Related Ocular Functional Parameters

Beyond the primary focus on IOP, some smaller-scale studies explored other physiological factors. Research in this area has primarily used observational and smaller crossover studies to examine parameters related to Ocular Blood Flow (OBF). These studies monitored physiological strain or stress in the eye, and some findings describe patterns observed in the studies related to changes in blood flow markers in these specific ocular tissues. However, the available data are still emerging and findings were mixed regarding whether these changes in blood flow markers were directly associated with corresponding, measurable patterns in standard visual function tests. This evidence contributes to understanding symptom patterns but research does not determine whether an individual will respond similarly.

---

What the Research Landscape Still Leaves Uncertain

Despite the wealth of data on IOP measurements, the research describes specific limitations in its structure. There is limited information for long-term outcomes regarding the medication’s effect on the slow progression of optic nerve damage and associated visual field loss over many years. Many functional studies, particularly those focused on ocular blood flow, had sample sizes that were modest and the findings were mixed regarding a direct functional pattern. Consequently, the certainty remains low regarding non-IOP outcomes.

Key Studies & References

1. Rational use of the fixed combination of dorzolamide – timolol in the management of raised intraocular pressure and glaucoma

Common questions about Zitodor (FAQ)

---

Q: Can Zitodor cause a bitter taste in my mouth?

Official product information indicates that taste perversion is a frequently reported adverse reaction. Patients may experience a bitter, sour, or unusual taste in the mouth after using the drops. This systemic effect is known to be associated with the use of this ophthalmic solution.

---

Q: Can children use Zitodor?

Official regulatory documents state that the safety and efficacy of Zitodor have not been established in children younger than two years of age. For children aged two years and older, a healthcare provider must determine the appropriate dosage and use. The medication is indicated for use in adults.

---

Q: Is it safe to drive after applying Zitodor?

Regulatory sources advise that side effects such as blurred vision, dizziness, or other visual disturbances may occur shortly after application. Patients experiencing these effects should exercise caution and avoid potentially hazardous activities, such as driving or operating machinery, until the visual disturbances resolve.

---

Q: Can I stop using Zitodor once my eye pressure is normal?

Official guidance cautions against discontinuing the medication suddenly without instruction from a healthcare provider. To help maintain consistent pressure control, continued use is typically required, even if the patient feels well, as stopping treatment may cause the underlying eye condition to worsen.

---

Q: How do I know if the eye drops are still sterile?

According to official guidance, maintaining sterility depends on proper handling of the bottle. Contamination can occur if the bottle tip touches the eye, eyelid, or any other surface. This kind of contamination can introduce bacteria, which may lead to serious eye infections and potential vision loss; therefore, following careful hygiene helps prevent contamination.

---

Q: What is the correct way to dispose of the old medicine?

To dispose of unused or expired Zitodor, regulatory information states that the product must not be flushed down a sink or toilet. It should instead be disposed of through an authorized drug take-back program or as directed by local waste disposal regulations.

---

Q: Why do I need to close my eyes and press on the tear duct after using the drops?

This technique, where the eye is closed and gentle pressure is applied to the inner corner (tear duct), is intended to help keep the medicine in the eye. This process also minimizes the amount of the drug that is absorbed systemically into the rest of the body.

---

Q: What should I do if I accidentally swallow the eye drops?

If an accidental overdose or swallowing of the ophthalmic solution occurs, official advice states that immediate medical help should be sought and a poison control center contacted. The systemic absorption of the active ingredients warrants prompt evaluation.

---

Q: Is it normal for my eyes to feel like they are burning or stinging after I apply the drops?

Yes, regulatory documents indicate that ocular burning or stinging is one of the most common adverse reactions reported, affecting up to 30% of patients. While common, patients are advised to seek guidance from their healthcare provider if the stinging is severe or persistent.

How to Store and Dispose of Zitodor

Zitodor (Dorzolamide/Timolol Ophthalmic Solution) must be stored strictly according to official regulatory guidelines to maintain its stability and sterility.

---

Storage Requirements

The medicine should be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). It must be kept in its original container, protected from light and moisture, and kept from freezing.

Storage Constraint	Regulatory Requirement
Temperature	Store between 20 C to 25 C.
Container	Keep in original container and tightly closed
Child Safety	Keep out of the sight and reach of children

---

Stability and Disposal

Once the multi-dose bottle is first opened, any remaining solution must be discarded after 30 days.

For disposal of unused or expired product, the medicine must not be poured down a sink or toilet (wastewater). Instead, the product must be disposed of through an authorized drug take-back program or as directed by local waste disposal regulations.